David Huo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
David Huo has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Albert C. Koong
Department of Gastrointestinal Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
8 shared publications - Boyi Gan
Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
8 shared publications - Chao Mao
Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
8 shared publications - Dadi Jiang
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
8 shared publications - Girish Halemirle Rajacharya
Department of Oncology Science, University of Oklahoma College of Medicine, University of Oklahoma Health Sciences, Oklahoma City, Oklahoma
8 shared publications - Guang Lei
Furong Laboratory, Central South University, Changsha, China
8 shared publications
Latest Publications
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from DHODH-Mediated Suppression of Ferroptosis Supports Radioresistance and Represents a Therapeutic Vulnerability in Lung Cancer
Primer sequences used for gene expression analyses
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from DHODH-Mediated Suppression of Ferroptosis Supports Radioresistance and Represents a Therapeutic Vulnerability in Lung Cancer
Primer sequences used for gene expression analyses
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from DHODH-Mediated Suppression of Ferroptosis Supports Radioresistance and Represents a Therapeutic Vulnerability in Lung Cancer
Representative images of immunohistochemical staining for Ki-67 in tumor tissues across the indicated treatment groups
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from DHODH-Mediated Suppression of Ferroptosis Supports Radioresistance and Represents a Therapeutic Vulnerability in Lung Cancer
Representative images of immunohistochemical staining for Ki-67 in tumor tissues across the indicated treatment groups
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from DHODH-Mediated Suppression of Ferroptosis Supports Radioresistance and Represents a Therapeutic Vulnerability in Lung Cancer
Body weight measurements of mice during treatment, indicating tolerability of the indicated therapeutic regimens
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from DHODH-Mediated Suppression of Ferroptosis Supports Radioresistance and Represents a Therapeutic Vulnerability in Lung Cancer
Body weight measurements of mice during treatment, indicating tolerability of the indicated therapeutic regimens
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from DHODH-Mediated Suppression of Ferroptosis Supports Radioresistance and Represents a Therapeutic Vulnerability in Lung Cancer
Genetic or pharmacologic inhibition of DHODH, in combination with IFN-γ treatment, enhances radiosensitivity in lung cancer cells, as determined by cell viability and clonogenic survival assays
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from DHODH-Mediated Suppression of Ferroptosis Supports Radioresistance and Represents a Therapeutic Vulnerability in Lung Cancer
Genetic or pharmacologic inhibition of DHODH, in combination with IFN-γ treatment, enhances radiosensitivity in lung cancer cells, as determined by cell viability and clonogenic survival assays
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from DHODH-Mediated Suppression of Ferroptosis Supports Radioresistance and Represents a Therapeutic Vulnerability in Lung Cancer
Quantification of immunohistochemical staining signals, including 4-HNE, Ki-67, and cleaved caspase-3, in tumor tissues from the indicated treatment groups
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from DHODH-Mediated Suppression of Ferroptosis Supports Radioresistance and Represents a Therapeutic Vulnerability in Lung Cancer
Quantification of immunohistochemical staining signals, including 4-HNE, Ki-67, and cleaved caspase-3, in tumor tissues from the indicated treatment groups
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from DHODH-Mediated Suppression of Ferroptosis Supports Radioresistance and Represents a Therapeutic Vulnerability in Lung Cancer
CREB1 and CREB2 expression levels are positively associated with DHODH expression following radiotherapy, based on correlation analyses of gene expression data
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from DHODH-Mediated Suppression of Ferroptosis Supports Radioresistance and Represents a Therapeutic Vulnerability in Lung Cancer
CREB1 and CREB2 expression levels are positively associated with DHODH expression following radiotherapy, based on correlation analyses of gene expression data
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from DHODH-Mediated Suppression of Ferroptosis Supports Radioresistance and Represents a Therapeutic Vulnerability in Lung Cancer
Radiation increases DHODH expression and enzymatic activity in the indicated lung cancer models, as assessed by immunoblotting and activity assays
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from DHODH-Mediated Suppression of Ferroptosis Supports Radioresistance and Represents a Therapeutic Vulnerability in Lung Cancer
Radiation increases DHODH expression and enzymatic activity in the indicated lung cancer models, as assessed by immunoblotting and activity assays
- 11 May 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
- p. OF1-OF16
DHODH-Mediated Suppression of Ferroptosis Supports Radioresistance and Represents a Therapeutic Vulnerability in Lung Cancer
Radiotherapy (RT) is a mainstay in the treatment of solid tumors, including lung cancer, yet the long-term efficacy is often limited by radioresistance. RT promotes multiple different cell death processes, and gaining mechanistic insights into how metabolic cell death pathways like ferroptosis contribute to resistance could enable the development of effective modulators of radiation sensitivity. In this study, through metabolomic and functional analyses, we identified dihydroorotate dehydrogenase (DHODH) as a critical regulator of radioresistance in lung cancer. DHODH expression was induced by radiation in a cAMP response element-binding protein–dependent manner, and both radiation exposure and acquired radioresistant states were associated with elevated DHODH activity. DHODH promoted radioresistance in part by generating ubiquinol, a mitochondrial lipid antioxidant that suppresses ferroptosis, and by supporting DNA repair through its role in de novo pyrimidine synthesis. Although DHODH inhibition alone had limited therapeutic effect, its combination with interferon-gamma (IFNγ; delivered directly or via anti–PD-1 immunotherapy) synergistically enhanced RT-induced ferroptosis and overcame radioresistance in preclinical models. These findings reveal a metabolic mechanism of radioresistance driven by DHODH-mediated ferroptosis defense and provide a rationale for combining DHODH inhibitors with RT and immunotherapy in lung cancer and potentially other solid tumors. Significance: DHODH acts as a metabolic barrier to ferroptosis-driven radiosensitivity and can be targeted in combination with radiotherapy and immunotherapy as a strategy for treating lung cancer.
- 11 May 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
- p. OF1-OF16
DHODH-Mediated Suppression of Ferroptosis Supports Radioresistance and Represents a Therapeutic Vulnerability in Lung Cancer
Radiotherapy (RT) is a mainstay in the treatment of solid tumors, including lung cancer, yet the long-term efficacy is often limited by radioresistance. RT promotes multiple different cell death processes, and gaining mechanistic insights into how metabolic cell death pathways like ferroptosis contribute to resistance could enable the development of effective modulators of radiation sensitivity. In this study, through metabolomic and functional analyses, we identified dihydroorotate dehydrogenase (DHODH) as a critical regulator of radioresistance in lung cancer. DHODH expression was induced by radiation in a cAMP response element-binding protein–dependent manner, and both radiation exposure and acquired radioresistant states were associated with elevated DHODH activity. DHODH promoted radioresistance in part by generating ubiquinol, a mitochondrial lipid antioxidant that suppresses ferroptosis, and by supporting DNA repair through its role in de novo pyrimidine synthesis. Although DHODH inhibition alone had limited therapeutic effect, its combination with interferon-gamma (IFNγ; delivered directly or via anti–PD-1 immunotherapy) synergistically enhanced RT-induced ferroptosis and overcame radioresistance in preclinical models. These findings reveal a metabolic mechanism of radioresistance driven by DHODH-mediated ferroptosis defense and provide a rationale for combining DHODH inhibitors with RT and immunotherapy in lung cancer and potentially other solid tumors. Significance: DHODH acts as a metabolic barrier to ferroptosis-driven radiosensitivity and can be targeted in combination with radiotherapy and immunotherapy as a strategy for treating lung cancer.